Rett Syndrome – Pipeline Review, H2 by Gosreports 2025

1
Global Automotive Relay Market Research Report
2016
2
Rett Syndrome Pipeline Review, H2 by Gosreports
2025 Global Markets Directs latest
Pharmaceutical and Healthcare disease pipeline
guide Rett Syndrome Pipeline Review, H2 2016,
provides an overview of the Rett Syndrome
(Central Nervous System) pipeline
landscape. Rett syndrome is a neurodevelopmental
disorder. This is caused by genetic mutation on
MECP2 gene. Rett syndrome is described in four
stages Stage I or early onset, Stage II or rapid
destruction, Stage III, or the plateau and Stage
IV, or the late motor deterioration stage.
Symptoms include slowed growth, loss of normal
movement and coordination, loss of communication
abilities, breathing problems, pain, irregular
heartbeat and seizures. Risk factors include
family history and gender. Treatment includes
disease modifying drugs. Request for sample of
this research report http//www.gosreports.com/re
tt-syndrome-pipeline-review-h2-2016/
3
Some points from TOC Part I Automotive Relay
Overview Table of Contents Table of Contents
2 List of Tables 6 List of Figures 6 Introduction
8 Global Markets Direct Report Coverage 8 Rett
Syndrome Overview 9 Therapeutics Development
10 Pipeline Products for Rett Syndrome Overview
10 Pipeline Products for Rett Syndrome
Comparative Analysis 11 Rett Syndrome
Therapeutics under Development by Companies
12 Rett Syndrome Therapeutics under
Investigation by Universities/Institutes 14 Rett
Syndrome Pipeline Products Glance 15 Late Stage
Products 15 Clinical Stage Products 16 Early
Stage Products 17 Unknown Stage Products 18 Rett
Syndrome Products under Development by
Companies 19
4
Some points from TOC Edison Pharmaceuticals,
Inc. 23 Eloxx Pharmaceuticals, Ltd. 24 GW
Pharmaceuticals Plc 25 Mitochon Pharmaceuticals,
Inc. 26 Mitsubishi Tanabe Pharma Corporation
27 Neuren Pharmaceuticals Limited 28 Neurolixis
Inc. 29 Newron Pharmaceuticals S.p.A. 30 OPKO
Health, Inc. 31 Oryzon Genomics SA
32 PharmatrophiX, Inc. 33 Raptor Pharmaceutical
Corp. 34 Recursion Pharmaceuticals, LLC 35 Sage
Therapeutics, Inc. 36 Ultragenyx Pharmaceutical
Inc. 37 Rett Syndrome Therapeutics Assessment
38 Assessment by Monotherapy Products
38 Assessment by Target 39
5
amlexanox Drug Profile 47 Product Description
47 Mechanism Of Action 47 RD Progress
47 ANAVEX-273 Drug Profile 48 Product
Description 48 Mechanism Of Action 48 RD
Progress 48 Bryostatin-1 Drug Profile
57 Product Description 57 Mechanism Of Action
57 RD Progress 57 CPT-157633 Drug Profile
61 Product Description 61 Mechanism Of Action
61 RD Progress 61 cysteamine DR Drug Profile
62 Product Description 62 Mechanism Of Action
62 RD Progress 62
6
ELX-02 Drug Profile 71 Product Description
71 Mechanism Of Action 71 RD Progress
71 fingolimod hydrochloride Drug Profile
72 Product Description 72 Mechanism Of Action
72 RD Progress 72 Gene therapy to Activate MECP2
for Rett Syndrome Drug Profile 78 Product
Description 78 Mechanism Of Action 78 RD
Progress 78 LM-22A4 Drug Profile 79 Product
Description 79 Mechanism Of Action 79 RD
Progress 79 MP-101 Drug Profile 80 Product
Description 80 ..................................
...........
7
More related reports http//www.gosreports.com/re
tt-syndrome-pipeline-review-h2-2016/ About
GosreportsGos International Inc. is one of the
leading distributors of market research reports
in the world today. We host more than 40,000
research products from the worlds top
publication houses.Our web-based platform offers
an unmatched collection of market research
reports, company reviews, databooks, articles,
periodical publications, databases, and much
more, delivered by the successful and
well-established publishers with whom we are
currently in partnership.Contacts UsJoanna
Executive - International Business and partner
RelationsE-mail info_at_gosreports.com Tel
001-510-400-8520Web http//www.gosreports.com